The new frontiers of drug therapy
The future of oncological therapies lies in prevention: the earlier we are able to diagnose the disease, the better the outcome of the treatment will be. This is especially true for cancers that are initially asymptomatic and therefore difficult to diagnose, such as lung cancer.
It is discussed in "Prevention and precision medicine: the case of lung cancer" live on the web Friday 25 September at 10: 00-10: 30. Speakers Mirko Merletti, Vice President Head of Oncology, Astra Zeneca Italia; Silvia Novello, Full Professor of Medical Oncology at the San Luigi Gonzaga University Hospital of Turin; Giorgio Scagliotti, Full Professor of Medical Oncology at the University of Turin.
"The importance of timely intervention to combat oncological pathology clearly emerges from the recent clinical trials carried out – explains Mirko Merletti, Vice President Head of Oncology, Astra Zeneca Italia. "Particularly encouraging results come from the use of target drugs in early disease settings: the response of the treated cases is surprisingly positive".
We are going through a phase of great innovation in drug therapies for cancer diseases. “On the one hand – continues Merletti – precision medicine is in formidable expansion, with the development of molecules capable of intervening on specific genetic mutations; on the other hand, immunoncology is growing faster and faster, with new drugs that act on the immune system, turning on or off receptors to fight the disease. From the recently presented ESMO, European Society for Medical Oncology data, it emerges that immunotherapy increases patient survival and slows the progression of lung cancer; at the same time, precision medicine is moving towards an increasingly personalized therapy, tailored to the characteristics of the patient, which allows the treatment to be modulated to obtain a more effective response from the individual person's organism.
"The search for new therapies and new pharmacological approaches is fundamental – comments Merletti – but it is equally important to invest in screening to intercept cases of silent, asymptomatic disease, bring them out and start treatment at a stage in which the tumor has not yet become aggressive, when the organism is stronger and can counteract the progression of the disease. For this reason, it is important to disseminate scientifically correct information directed to patients, including through dissemination events, accessible to a general public, which must be made aware of the importance of prevention. Sharing specific expertise with the public, which must become widespread knowledge, is the first step to improve the effectiveness of treatments: a better informed public is made up of more aware and healthier patients ".
Prevention and precision medicine: the case of lung cancer
Live web – Friday 25 September 2020 – 10:00
This year's edition is only online. Click here to participate in the event.